Podcasts about Amyloid

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZFA865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.Navigating Advances in Alzheimer's Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZFA865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.Navigating Advances in Alzheimer's Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZFA865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.Navigating Advances in Alzheimer's Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZFA865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.Navigating Advances in Alzheimer's Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZFA865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.Navigating Advances in Alzheimer's Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZFA865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.Navigating Advances in Alzheimer's Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZFA865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.Navigating Advances in Alzheimer's Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/ZFA865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.Navigating Advances in Alzheimer's Disease: Practical Strategies for Integrating New Diagnostic Tools and Amyloid-Targeting Therapies Into Patient Care In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

In this Healthed lecture, Professor Henry Brodaty explains the evidence for the effectiveness of Donanemab in slowing cognitive and functional decline, with the greatest benefit being seen in early-stage patients. In addition, he will discuss the practical aspects of the treatment including patient selection, assessment, referral process as well as how the monthly IV infusions are delivered, monitored, and potential side effects. Professor Brodaty will also address the reality that the effectiveness of donanemab is not universal and careful patient selection and managing expectations is important.See omnystudio.com/listener for privacy information.

Sébastien LecommandouxCollège de FranceInnovation technologique Liliane Bettencourt (2024-2025)Année 2024-2025Colloque - Advancing Biomaterials: Biomimetic and Biohybrid InnovationsRaffaele Mezzenga : Amyloid-metal biohybrids for health and environmental remediationRaffaele MezzengaProfesseur, ETH ZurichRésuméAmyloid fibrils interact with metal ions via metal-ligand supramolecular interactions whose energy is of the order of tens to hundreds of KBT. The occurrence of the 20 essential amino acids in food-based amyloid fibrils derived from inexpensive animal and plant proteins, including from food waste, combined with the extreme aspect ratio of the amyloids, allow for an affordable, yet universal toolbox to produce multifunctional hybrids which can serve in a multitude of applications and technologies. In this talk I will provide several examples of food amyloid fibrils interacting with metal ions and nanoparticles for both health and environmental remediation, some of which have made it into real technologies. Taking β-lactoglobulin amyloids as a model amyloid system derived from whey, a by-product of cheese making process, I will show how metal ions can be adsorbed from water and wastewater solutions by amyloid-based filters for water purification purposes, or how gold ions can be adsorbed and processed from amyloid aerogels to recycle gold from e-waste. I will also show how iron atoms can be coordinated to β-lactoglobulin amyloids to deliver highly bioavailable Fe(II) for iron fortification, or to design hydrogels capable of performing cascade enzymatic reactions for alcohol detoxification in vivo. Raffaele MezzengaRaffaele Mezzenga is full professor at ETH Zurich since 2009. His research focuses on the self-assembly of proteins, polymers, liquid crystals, food and colloidal systems. He is a Highly Cited Researcher (Clarivate, 2023) in the cross-field discipline, with more than 450 publications and 20 patents. His work has been recognized by several prestigious international distinctions such as the 2017 Fellowship and the 2013 Dillon Medal by the American Physical Society, the 2013 Biomacromolecules/Macromolecules Young Investigator Award by the American Chemical Society, the 2011 American Oil Chemists' Society Young Scientist Research Award, and the 2004 Swiss Science National Foundation Professorship Award.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QPX865. CME/MOC/EBAC/NCPD/AAPA credit will be available until May 31, 2026.Implementing Amyloid-Targeting Treatment for Early AD: Strategies for Overcoming Real-World Challenges In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QPX865. CME/MOC/EBAC/NCPD/AAPA credit will be available until May 31, 2026.Implementing Amyloid-Targeting Treatment for Early AD: Strategies for Overcoming Real-World Challenges In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QPX865. CME/MOC/EBAC/NCPD/AAPA credit will be available until May 31, 2026.Implementing Amyloid-Targeting Treatment for Early AD: Strategies for Overcoming Real-World Challenges In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QPX865. CME/MOC/EBAC/NCPD/AAPA credit will be available until May 31, 2026.Implementing Amyloid-Targeting Treatment for Early AD: Strategies for Overcoming Real-World Challenges In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QPX865. CME/MOC/EBAC/NCPD/AAPA credit will be available until May 31, 2026.Implementing Amyloid-Targeting Treatment for Early AD: Strategies for Overcoming Real-World Challenges In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/QPX865. CME/MOC/EBAC/NCPD/AAPA credit will be available until May 31, 2026.Implementing Amyloid-Targeting Treatment for Early AD: Strategies for Overcoming Real-World Challenges In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This week on the show, we're have our sights set on healthy aging. What would it mean to be able to live to 80, 90 or 100 with our cognitive abilities intact and able to maintain an independent lifestyle right to the end of our days? We're joined by Beth Mormino and Anthony Wagner who lead the Stanford Aging and Memory Study, which recruits cognitively healthy older adults to understand what makes their brains particularly resilient — and how more of us could join them in living the dream of healthy aging.Learn MoreStanford Aging and Memory Study (SAMS)Stanford Memory LabMormino LabFurther ReadingAlzheimer's 'resilience signature' predicts who will develop dementia—and how fast (Knight Initiative for Brain Resilience, 2025)Latest Alzheimer's lab tests focus on memory loss, not brain plaques (NPR, 2025)ReferencesTrelle, A. N., ... & Wagner, A. D. (2020). Hippocampal and cortical mechanisms at retrieval explain variability in episodic remembering in older adults. eLife, 9:e55335. doi: 10.7554/eLife.55335 PDF | PMID:32469308Trelle, A. N., ..., Wagner, A. D., Mormino, E. C., & Wilson, E. N. (2025). Plasma Aβ42/Aβ40 is sensitive to early cerebral amyloid accumulation and predicts risk of cognitive decline across the Alzheimer's disease spectrum. Alzheimer's & Dementia, 21:e14442. PDF | PMID:39713875Sheng, J., ..., Mormino, E., & Wagner, A. D. (submitted). Top-down attention and Alzheimer's pathology impact cortical selectivity during learning, influencing episodic memory in older adults.  PreprintEpisode CreditsThis episode was produced by Michael Osborne at 14th Street Studios, with sound design by Morgan Honaker. Our logo is by Aimee Garza. The show is hosted by Nicholas Weiler at Stanford's Wu Tsai Neurosciences Institute and supported in part by the Knight Iniative for Brain Resilience.Get in touchWe want to hear from your neurons! Email us at at neuronspodcast@stanford.edu if you'd be willing to help out with some listener rSend us a text!Thanks for listening! If you're enjoying our show, please take a moment to give us a review on your podcast app of choice and share this episode with your friends. That's how we grow as a show and bring the stories of the frontiers of neuroscience to a wider audience. Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

Commentary by Dr. Nowell Fine.

Now that we have approved disease-modifying therapies for Alzheimer's disease (AD), what is the best way to work with patients, families, and colleagues to administer them? Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-future-clinical-roadmap-anti-amyloid-therapies-2025a10007h0/1?ecd=bdc_podcast_libsyn_mscpedu

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-triage-and-imaging-in-the-emergency-setting-for-patients-prescribed-anti-a-mabs/30022/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-how-to-manage-asymptomatic-aria/27043/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-nuances-of-microhemorrhages-when-evaluating-an-mri-for-aria/27041/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-when-is-a-headache-concerning-in-patients-prescribed-anti-a-mabs/27040/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-communicating-aria-risk-with-patients-considering-anti-a-therapy/27039/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-1-navigating-the-baseline-mri-for-anti-a-monoclonal-antibodies/27038/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-differential-diagnoses-and-potential-pitfalls-in-aria-evaluation/27042/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-differentiating-and-navigating-aria-vs-stroke-when-an-emergent-mri-is-unavailable/30023/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-how-to-manage-severe-aria/30024/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-how-to-interpret-and-manage-aria-h/27045/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-navigating-the-baseline-mri-for-anti-a-monoclonal-antibodies/27038/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-evolving-approaches-to-mitigate-aria-risk-in-patients-prescribed-anti-a-mabs/27044/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

This episode is for every woman who has watched a loved one battle Alzheimer's and wondered, "Is there anything I can do to prevent this?" The answer is yes.In part three of our four-part series on Alzheimer's prevention, we explore the latest pharmaceutical breakthroughs, the three-phase model of Alzheimer's progression, and why early intervention is everything.Tune in to discover what treatments are available, what's in the research pipeline, and how to evaluate options for yourself or a loved one.What to Listen For:[02:00] – The difference between treating Alzheimer's symptoms vs. modifying the disease itself[04:30] – The 3-phase model of Alzheimer's progression and why it matters for treatment[07:00] – The crucial difference between early-onset and late-onset Alzheimer's[10:45] – Dr. Rudy Tanzi's “sink metaphor” for how Alzheimer's develops in the brain[13:00] – The first-ever fully FDA-approved drugs to slow cognitive decline[15:30] – Who qualifies for these new Alzheimer's drugs—and who doesn't[17:00] – The serious risks and side effects of monoclonal antibody treatments[20:15] – Why these drugs only work in the early stages of Alzheimer's[22:00] – The staggering cost of new treatments and what insurance may (or may not) cover[25:00] – The future of Alzheimer's treatment: What's in the research pipeline right nowEarly is everything. This episode has covered the latest in Alzheimer's treatments, but the most important takeaway is that early intervention gives you the most options. Whether through lifestyle changes, early screenings, or new pharmaceutical breakthroughs, there are steps you can take today to protect your brain health.If this episode resonated with you, be sure to subscribe to Happy and Healthy with Amy Lang, and check out the links below for more resources!From The EpisodeEpisode 274: The Latest Alzheimer's Treatments (2025 Update)RESOURCES: Book a FREE Discovery Call with Amy Lang Order Amy's book Thoughts Are Habits Too: Master Your Triggers, Free Yourself From Diet Culture, and Rediscover Joyful Eating. Follow Amy on Instagram @habitwhisperer

In this episode, Dr. Valentin Fuster highlights a groundbreaking study on acoramides, a novel treatment for transthyretin amyloid cardiomyopathy (ATTR), which shows significant reductions in mortality and cardiovascular hospitalizations compared to a placebo. Experts discuss the clinical implications, comparing acoramides to the previously approved tafamidis, noting exciting advancements in treatments for a once-untreatable disease.

CardioNerds Cardiac Amyloidosis Series Chair Dr. Rick Ferraro and Episode Lead Dr. Anna Radakrishnan discuss the biology of transthyretin amyloid cardiomyopathy (ATTR-CM ) with Dr. Daniel Judge.  Notes were drafted by Dr. Anna Radakrishnan. The audio was engineered by student Dr. Julia Marques.  This episode provides a comprehensive overview of transthyretin (ATTR) cardiac amyloidosis, a complex and rapidly evolving disease process. The discussion covers the key red flags for cardiac amyloidosis, the diagnostic pathway, and the implications of hereditary versus wild-type ATTR. Importantly, the episode delves into the current and emerging therapies for ATTR, including stabilizers, gene silencers, and promising treatments like CRISPR-Cas9 and antibody-based approaches. Dr. Judge shares his insights and excitement about the rapidly advancing field, highlighting the need for early diagnosis and the potential to improve long-term outcomes for patients with this condition.  Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey.  US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here.  CardioNerds Cardiac Amyloid PageCardioNerds Episode Page Pearls: - Biology of Transthyretin amyloid cardiomyopathy Maintain a high index of suspicion! Look for subtle (yet telling) signs like ventricular hypertrophy, discordant EKG findings, bilateral carpal tunnel syndrome, and spontaneous biceps tendon rupture.  Utilize the right diagnostic tests. Endomyocardial biopsy remains the gold standard, but non-invasive tools like PYP scan with SPECT imaging and genetic testing are essential for accurate diagnosis.  Differentiating hereditary from wild-type ATTR is critical, as genetic forms may have a more aggressive course and familial implications.  Early diagnosis and intervention significantly improve prognosis, making vigilance in screening and prompt treatment initiation essential.  The future is now! Cutting-edge therapies are transforming the treatment landscape, including TTR stabilizers, gene silencers, and emerging technologies like CRISPR-Cas9 and antibody-based treatments.  Notes - Biology of Transthyretin amyloid cardiomyopathy What is transthyretin amyloid (aTTR) and how is it derived?  Transthyretin (TTR) is a transport protein primarily synthesized by the liver, responsible for carrying thyroid hormones (thyroxine) and retinol (vitamin A) in the blood. It circulates as a tetramer, composed of four identical monomers, which is essential for its stability and function.  In transthyretin amyloid (ATTR) amyloidosis, the TTR protein becomes unstable, leading to its dissociation into monomers. These monomers misfold and aggregate into insoluble amyloid fibrils, which deposit extracellularly in tissues such as the heart, nerves, and gastrointestinal tract. This progressive amyloid deposition leads to organ dysfunction, including restrictive cardiomyopathy and neuropathy.  There are two main forms of ATTR amyloidosis: hereditary (variant) and wild-type (senile) ATTR.  Hereditary ATTR (ATTRv) is caused by mutations in the TTR gene. These mutations destabilize the TTR tetramer, making it more prone to dissociation. This increases misfolding and amyloid fibril formation, resulting in systemic amyloid deposition.   Wild-type ATTR (ATTRwt) occurs without genetic mutations and is primarily age-related. Over time, even normal TTR tetramers can become unstable, leading to gradual misfolding and amyloid deposition, particularly in the heart. ATTRwt is a common but often underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF) in elderly individuals.  How does aTTR lead to deleterious effects in the heart and other organ systems?    Transthyretin amyloidosis leads to organ dysfunction through the deposition of misfolded TTR protein as amyloid fib...

In this conversation, Dr. Sam Sigoloff interviews Richard Hirschman, a trade embalmer, about the alarming discovery of unusual clots found in deceased individuals, particularly in relation to the COVID-19 pandemic. Hirschman shares his experiences and findings, detailing the characteristics of these clots, their potential links to amyloid proteins, and the implications for public health. The discussion highlights the role of embalmers in uncovering medical anomalies and raises concerns about the broader health impacts of these findings. In this segment of the conversation, Dr. Sam Sigoloff and Richard Hirschman delve into the perplexing phenomenon of clot formation in both veins and arteries, particularly in the context of COVID-19. They discuss the implications of autopsy findings, the unusual presence of amyloid clots, and the potential connections to vaccines. The dialogue also touches on the role of lipid nanoparticles and the broader implications of emergency use authorization in the context of public health and safety. In this conversation, Richard Hirschman and Dr. Sam Sigoloff delve into the alarming discovery of micro-clots in blood samples, potentially linked to vaccines and COVID-19. They discuss the challenges faced in medical research, the erosion of trust in the medical system, and the ethical dilemmas surrounding the reporting of vaccine-related injuries. The dialogue emphasizes the need for further investigation into the causes of these clots and a collective call to action for the medical community and society at large.TakeawaysRichard Hirschman has documented over 200 unusual clots since 2021.The clots are unlike anything seen prior to the pandemic.Amyloid proteins are being found in these clots, raising health concerns.The presence of amyloid in the bloodstream is alarming.There is a potential link between these clots and vaccine injuries.Embalmers are observing changes in blood that are not typical post-mortem clots.The clots are dense and do not fall apart like normal clots.There is a need for further research into the nature of these clots.The conversation highlights the importance of embalmers in medical discoveries.The findings could explain various health issues being reported post-vaccination. Autopsies typically focus on organ examination, not detailed vascular analysis.Clots are usually found in veins, not arteries, raising concerns about new findings.The presence of amyloid in clots suggests a significant change in clot composition post-COVID.Vaccine-induced thrombotic thrombocytopenia is a rare but concerning phenomenon.Lipid nanoparticles may play a role in abnormal clotting mechanisms.Emergency use authorization was declared amidst a perceived attack on public health.The presence of amyloid-like structures in blood raises questions about vaccine safety.Research indicates a potential link between spike proteins and abnormal clotting.The discussion highlights the need for further investigation into vaccine-related health issues.The conversation emphasizes the importance of transparency in medical research and public health policies. There is a significant presence of micro-clots in blood samples.Micro-clots may be linked to a new blood-borne amyloid clotting syndrome.Observation and documentation are crucial in identifying unusual medical phenomena.Medical research faces challenges in funding and peer review processes.Trust in the medical system has been severely impacted by COVID-19 protocols.The correlation between vaccines and abnormal clots is a growing concern.Ethical dilemmas arise when reporting potential vaccine injuries.Not everyone experiences the same reactions to vaccines, but harm does occur.A spiritual perspective is essential in addressing the current health crisis.Community leaders must advocate for truth and transparency in medical practices.lf you like my t-shirt please get one here:
XL
https://www.ebay.com/itm/166498979030?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=p4ex0znwsqu&sssrc=4429486&ssuid=p4ex0znwsqu&var=&widget_ver=artemis&media=COPYLarge
https://www.ebay.com/itm/166498976051?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=p4ex0znwsqu&sssrc=4429486&ssuid=p4ex0znwsqu&var=&widget_ver=artemis&media=COPYMedium
https://www.ebay.com/itm/166498969796?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=p4ex0znwsqu&sssrc=4429486&ssuid=p4ex0znwsqu&var=&widget_ver=artemis&media=COPYSmall
https://www.ebay.com/itm/166498972939?mkcid=16&mkevt=1&mkrid=711-127632-2357-0&ssspo=p4ex0znwsqu&sssrc=4429486&ssuid=p4ex0znwsqu&var=&widget_ver=artemis&media=COPYIf you would like to purchase better than grass fed and grass finished beef that will never get mRNA injections, never get growth hormones and never get antibiotics check out mycleanbeef.com/afterhoursAs always please like, share and follow. Please check out my Patreon account (https://www.patreon.com/Afterhourswithdrsigoloff). This is mostly to help with the legal fees. Please consider contributing but if you are unable to donate money please give prayers.truthforhealth.org for COVID illness and long haulers syndrome treatment protocols. If you have a vaccine injury (from any vaccine or have any injury that you think may have any relation to any vaccine) please report in their civilian equivalent to VAERS.Patreon: https://www.patreon.com/Afterhourswithdrsigoloff 
Email: afterhours@1791.com
Instagram: @afterhourswithdrsigoloff
Clouthub: @DrSigoloff
TruthSocial: @DrSigoloff
Rumble: https://rumble.com/c/AfterHoursWithDrSigoloff
Youtube: https://www.youtube.com/channel/UCQ_ng3WYVhnctCYq6Rom07g
Givesendgo: https://www.givesendgo.com/G37EN

This week, we look at the new pharmaceuticals that the FDA has approved for treating Alzheimer disease. Although they are effective at removing amyloid plaques from the brain, they don't seem to help patients function better. Is it time to turn away from an exclusive focus on amyloid to consider other factors that might affect […]

Are you up to date on the new developments for emerging therapies for your patients with transthyretin amyloid cardiomyopathy (ATTR-CM)? Credit available for this activity expires: 12/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002007?ecd=bdc_podcast_libsyn_mscpedu

Guest Michael Greicius is an authority on Alzheimer's disease. He makes the case that while effective treatments have remained elusive, there are high hopes for new approaches that target tau proteins in the brain associated with the disease. In the meantime, to reduce Alzheimer's risk stay active, eat well, and manage circulatory risks, but skip genetic testing for now until better treatments emerge, Greicius tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your quest. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile:  Michael GreiciusConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michael Greicius, a professor of neurology and neurological sciences at Stanford University.(00:02:12) Understanding Alzheimer's DiseaseThe roles of amyloid and tau proteins in Alzheimer's disease.(00:04:53) Challenges in Developing TreatmentsThe multiple hurdles in creating Alzheimer's therapies.(00:09:07) Current Alzheimer's DrugsThe controversies and limitations of recently approved drugs.(00:10:23) Amyloid Plaques and Their ImpactWhy removing amyloid plaques hasn't improved patient outcomes.(00:14:29) Problems with Alzheimer's TrialsThe disconnect between amyloid removal and patient outcomes.(00:18:03) Functional Unblinding and Trial BiasHow functional unblinding affects trial results and drug evaluations.(00:23:51) The Potential of Targeting TauNew breakthroughs in targeting tau protein for Alzheimer's.(00:26:35) The Future of PreventionPotential preemptive treatments for Alzheimer's and their administration.(00:29:19) Lifestyle and Risk ReductionRecommendations for reducing risk of Alzheimer's disease.(00:31:43) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete EBAC/CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CAF865. EBAC/CME/AAPA/IPCE credit will be available until December 11, 2025.Alzheimer's Disease Case Conference: Acquiring New Skills and Visualizing Emerging Strategies for the Era of Amyloid-Targeting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

Dr. Eric Siemers, Medical Officer at Acumen Pharma, is developing a monoclonal antibody called sabirnetug that targets a specific toxic form of amyloid beta, Aβ oligomers. These oligomers are now believed to be a key driver of neuronal damage in Alzheimer's disease. The drug is in phase 2 clinical trials to evaluate its ability to slow cognitive decline in early-stage Alzheimer's patients and demonstrate the accuracy of biomarkers in identifying pathology before symptoms appear.   Eric explains, "We've identified, and this is a monoclonal antibody, a monoclonal antibody with a unique mechanism of action in that it targets what are called Aβ oligomers. And without going into all the details, these Aβ oligomers are now really felt to be the toxic species, the ones that cause the neurons to die, and the two drugs that have recently gotten approval sort of indirectly get at those toxic species, maybe one more than the other. But in our case, we're directly targeting what we think is the most toxic species. And so the progress in the field is wonderful, and nobody can say that it's not, or take anything away from that, but nobody's cured the disease either. Now we know we've got a toehold, we know an approach, and Acumen is using an antibody because of this unique target. We think of it as a next-generation treatment for Alzheimer's disease." "We've known about these Alzheimer's plaques for a long time, but what's more recent is understanding some of these intermediate species. And so these Aβ oligomers we target are oligo, meaning a few. So, anywhere from 2 to 200 of these Aβ stuck together. The Aβs are basically inherently sticky. And so the things we're most interested in are probably 10 of the Aβ together up to say 50, which seems to be the sweet spot." #AcumenPharmaceuticals #Alzheimers #ALZ #EndALZ #Sabirnetug #DrugDevelopment acumenpharm.com Download the transcript here

Dr. Eric Siemers, Medical Officer at Acumen Pharma, is developing a monoclonal antibody called sabirnetug that targets a specific toxic form of amyloid beta, Aβ oligomers. These oligomers are now believed to be a key driver of neuronal damage in Alzheimer's disease. The drug is in phase 2 clinical trials to evaluate its ability to slow cognitive decline in early-stage Alzheimer's patients and demonstrate the accuracy of biomarkers in identifying pathology before symptoms appear.   Eric explains, "We've identified, and this is a monoclonal antibody, a monoclonal antibody with a unique mechanism of action in that it targets what are called Aβ oligomers. And without going into all the details, these Aβ oligomers are now really felt to be the toxic species, the ones that cause the neurons to die, and the two drugs that have recently gotten approval sort of indirectly get at those toxic species, maybe one more than the other. But in our case, we're directly targeting what we think is the most toxic species. And so the progress in the field is wonderful, and nobody can say that it's not, or take anything away from that, but nobody's cured the disease either. Now we know we've got a toehold, we know an approach, and Acumen is using an antibody because of this unique target. We think of it as a next-generation treatment for Alzheimer's disease." "We've known about these Alzheimer's plaques for a long time, but what's more recent is understanding some of these intermediate species. And so these Aβ oligomers we target are oligo, meaning a few. So, anywhere from 2 to 200 of these Aβ stuck together. The Aβs are basically inherently sticky. And so the things we're most interested in are probably 10 of the Aβ together up to say 50, which seems to be the sweet spot." #AcumenPharmaceuticals #Alzheimers #ALZ #EndALZ #Sabirnetug #DrugDevelopment acumenpharm.com Listen to the podcast here

It's too soon to conclude anti-amyloid therapies are safe for use by Alzheimer's patients in the real world, even as early reports are encouraging, argues BioCentury Executive Editor Selina Koch on the latest BioCentury This Week podcast. Koch and colleagues discuss takeaways from this year's Clinical Trials on Alzheimer's Disease annual meeting, including conclusions from adverse event data for Leqembi lecanemab and what the true test of appropriate use and safety for the drug might look like.BioCentury's editors also assess Phase II data presented at CTAD by UCB that provide some of the first clues about what species of tau to target and in which patients. And they discuss what results of Tuesday's presidential contest in the U.S. will mean for FDA, as well as the state of play for China biotech as the industry continues to grind out its first bear market.View full story: https://www.biocentury.com/article/65407500:00 - Introduction01:23 - CTAD: Anti-amyloids14:22 - CTAD: UCB's tau data19:47 - FDA & the Election28:16 - China Summit DebriefTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Dr. Stephanie  welcomes neurophysiologist and former world-class athlete Louisa Nicola. Together, they dive into the critical topic of brain health, with a focus on cognitive decline, dementia, and Alzheimer's disease—conditions that disproportionately affect women. Louisa, founder of NeuroAthletics, brings her expertise in helping athletes and investors optimize their brain function.Episode Overview:0:00 Intro/Teaser3:08 Alzheimer's Disease9:50 The Role of Amyloid and Tau Tangles24:18 Protecting Brain Health Against Alzheimer's28:06 Benefits of Exercise on Brain Health42:16 Strength and Neurocognitive Training52:48 Optimizing Brain Health With Omega-3s56:51 Debunking Myths About Creatine1:01:01 Optimizing Brain Health With Nutrition1:13:36 The Power of Social Relationships1:21:27 Connecting With Louisa Nicola-------------- NOW OPEN! EVEN BETTER! PREMIUM MEMBERSHIP: Subscribe at https://estima.supercast.com/ --------------Resources mentioned in this episode can be found at https://drstephanieestima.com/podcasts/womens-brain-health-cognitive-decline-dementia-alzheimers-with-louisa-nicola/Bio:Louisa Nicola is a neurophysiologist, human performance coach, and the founder of Neuro Athletics, a consulting firm that works with elite athletes and high-level professionals to optimize brain health and performance. With a background as a former world-class triathlete representing Australia, she transitioned into neuroscience, earning her Master of Medicine in neurophysiology from the University of Sydney. Louisa now focuses on helping athletes and investors achieve peak cognitive and physical performance through cutting-edge neuroscience strategies, including EEG scans, lab tests, and cognitive assessments. She is currently pursuing her doctorate, studying the effects of resistance exercise on brain health. Louisa is passionate about optimizing brain function and longevity, particularly in women, by focusing on sleep, nutrition, and exercise.We are grateful to our sponsors:BON CHARGEWhether you're an athlete looking to recover from intense workouts, a muscle mommy looking for some relief from the delayed onset muscle soreness, or just looking for relief from everyday muscle tension, the new Boncharge cold and heat therapy massage gun is your new best friend. Head over to https://BonCharge.com/better and use discount code BETTER at checkout for a 15% discount.TIMELINEFeeling tired and having no energy does not have to be your fate. Mitopure is a supplement and skin health line that helps improve energy at the level of the mitochondria so that you can continue to engage in the activities you love. Go to https://timelinenutrition.com/better and use code BETTER to get 10% off your order.COLDTUREEmbrace the cold with Coldture, the simplest and most fun way to feel the benefit of cold water immersion from the comfort of your home without having to load up ice in the bathtub. Head on over to https://coldture.com/drstephanie and use code DRSTEPHANIE to get an exclusive discount.

Can Alzheimer's really be optional? Join Dr. Dale Bredesen and Louisa Nicola as they dive into cutting-edge research and practical strategies to prevent cognitive decline. In this eye-opening episode, you'll discover why Alzheimer's doesn't have to be inevitable.Dr. Bredesen reveals the power of proactive steps—like advanced blood tests, genetic risk assessments, and lifestyle changes—that can reshape your brain health. From the role of the APOE gene to inflammation and detoxification, you'll learn how to take control of your cognitive future.If you're ready to challenge the narrative that Alzheimer's is unavoidable, this episode is for you. Timestamps0:00 Alzheimer's Prevention Through Lifestyle and Supplements3:02 Alzheimer's Disease as an Optional Condition Through Early Intervention9:47 Maui Nui Venison Sticks: The Ultimate On-The-Go Protein Snack12:05 Understanding Alzheimer's Disease and Its Underlying Causes15:40 Understanding Alzheimer's as a Network Insufficiency and Its Causes20:53 Metabolic Flexibility and Its Role in Cognitive Health25:47 Lifestyle Factors and Genetic Risks in Alzheimer's Prevention35:27 Inflammation's Role in Alzheimer's and Environmental Impact on Health44:21 Tau and Amyloid as Antimicrobial Peptides in Alzheimer's Disease49:56 Exploring Links Between MS, Alzheimer's, and Immune Responses57:15 Reversing Alzheimer's Through Nutrients, Detox, and Lifestyle Changes1:04:51 Innovations in Brain Health and Alzheimer's PreventionMomentous - Use code NEURO to get 20% off your order - https://www.livemomentous.com/neuroMaui Nui Venison - Use code NEURO to get 20% off https://mauinuivenison.com/pages/NEUROThe Neuro Athletics Newsletter Instagram: @louisanicola_Twitter : @louisanicola_YouTube: @Louisa NicolaThe Neuro Experience Podcast is proud to have hosted: Dr Andrew Huberman, Dr Gabrielle Lyon, Dr Layne Norton, Thomas DeLauer, Shawn Stevenson, Dr. Rocio Salas-Whalen, Saad Alam, Uma Naidoo, Dr. Lanna Cheuck, Angela Lee Pucci, Jillian Turecki, Dr. Jordan Feigenbaum, Dr. Darren Candow, Dr. Sue Varma, Evy Poumpouras, Dr Casey Means, Renee Deehan, Dr Chris Palmer, Dr Charles Brenner, Dr Joe Zundell

Dr. Steven DeKosky is professor of Alzheimer's research at the University of Florida College of Medicine and Deputy Director of the McKnight Brain Institute at that institution. He also is a professor of neurology and neuroscience there. Previously, he served as vice president and dean of the University of Virginia School of Medicine and was chairperson of the department of neurology at the University of Pittsburgh. Part 2 For the short-term, with mild to moderate traumatic injury you can have altered synaptic structure and function. For the longer term, chronic inflammation and chronic oxidative stress can lead to subsequent degeneration and also some chronic microglial activation, which may turn on mechanisms that you do not necessarily want, including cleaning up partially injured neurons that may recover. Especially in patients who get the disease in an older age, there is other pathology in the CTE. There are nerve fibrillary tangle and Lewy body.  Amyloid beta can be elevated in both white matter and grey matter and might add to the cascade that is thought amyloid leads to, which leads to degeneration especially Alzheimer's disease, but cannot prove it. Participants in contact sports all are at significant risk. APOE 4 increases the risk of Alzheimer's disease and the risk of tau deposition. Currently, when patients arrive for rehabilitation, they are going to have things a lot better described than was the case previously.  We can look at disruption of structures, see hemorrhage and inflammation. We know that CTE is not a new disease, but we do see the pathology in other contact sports and we do not view it in autopsy series unless the individual had a history or repetitive head injury. A Question & Answer period followed.

In episode 584, Mike and James invite Tina Korownyk back to the podcast to talk about the evidence for amyloid-targeting monoclonal antibodies in mild cognitive impairment or Alzheimer's dementia. Unfortunately, the evidence shows these medications don't seem to have a clinically important effect and do have some harms. Have a listen as we give you […]

Welcome back to today's Friday Review where I'll be breaking down the best of the week!   I'll be sharing specifics on these topics:   Summer Detox Starts Soon! Borgusi Treadmill (product review) The Mountain is You (book review) Beta Amyloid Plaque & Brain Health(research) Sneaky Labeling for Aspartame (research)   For all the details tune in to today's Cabral Concept 3052 – Enjoy the show and let me know what you thought! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3052 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!